JANX - Cancer-Focused Janux Therapeutics Stock Remains Undervalued Despite Price Surge After Study Data: Analyst | Benzinga
On Monday, Janux Therapeutics Inc (NASDAQ:JANX) released updated data for its JANX007 in metastatic castration-resistant prostate cancer and JANX008 in late-stage solid tumors.
JANX007 is in a Phase 1a trial in heavily pretreated subjects with advanced or metastatic prostate cancer (mCRPC).
- As of February 12, 2024, 23 subjects were treated with JANX007 in the dose escalation portion of the Phase 1a trial. An increasing depth of prostate-specific antigen (PSA) declines, RECIST responses at higher doses were observed, and a favorable safety profile was maintained.
- At a starting dose ? 0.1 mg, 14 of 18 (78%) subjects achieved PSA30 declines, and 10 of 18 (56%) subjects achieved PSA50 declines.
- At a starting step dose of ? 0.2 mg, 6 of 6 (100%) subjects achieved PSA30 declines, and 5 of 6 (83%) subjects achieved PSA50 declines.
- Initial step doses of JANX007 ? 0.2 mg drove deeper and more durable PSA responses, including one subject that achieved a PSA90 decline.
- Cytokine Release ...